Pharmacological signatures of the reduced incidence and the progression of cognitive decline in ageing populations suggest the protective role of beneficial polypharmacy

Autoři: Anatoly L. Mayburd aff001;  Mathilda Koivogui aff003;  Ancha Baranova aff002
Působiště autorů: Neurocombinatorix, Alexandria, Virginia, United States of America aff001;  George Mason University, School of Systems Biology, Colgan Hall, MSN 3E1 George Mason University, Manassas, Virginia, United States of America aff002;  Neurocombinatorix, Alexandria, Virginia, United States of America aff003;  Research Centre for Medical Genetics, Moscow, Russia aff004
Vyšlo v časopise: PLoS ONE 14(11)
Kategorie: Research Article
doi: 10.1371/journal.pone.0224315


Preventive treatments for dementia are warranted. Here we show that utilization of certain combinations of prescription medications and supplements correlates with reduced rates of cognitive decline. More than 1,900 FDA-approved agents and supplements were collapsed into 53 mechanism-based groups and traced in electronic medical records (EMRs) for >50,000 patients. These mechanistic groups were aligned with the data presented in more than 300 clinical trials, then regression model was built to fit the signals from EMRs to clinical trial performance. While EMR signals of each single agents correlated with clinical performance relatively weakly, the signals produced by combinations of active compounds were highly correlated with the clinical trial performance (R = 0.93, p = 3.8 x10^-8). Higher ranking pharmacological modalities were traced in patient profiles as their combinations, producing protective complexity estimates reflecting degrees of exposure to beneficial polypharmacy. For each age strata, the higher was the protective complexity score, the lower was the prevalence of dementia, with maximized life-long effects for the highest regression score /diversity compositions. The connection was less strong in individuals already diagnosed with cognitive impairment. Confounder analysis confirmed an independent effect of protective complexity in multivariate context. A sub-cohort with lifelong odds of dementia decreased > 5-folds was identified; this sub-cohort should be studied in further details, including controlled clinical trials. In short, our study systematically explored combinatorial preventive treatment regimens for age-associated multi-morbidity, with an emphasis on neurodegeneration, and provided extensive evidence for their feasibility.

Klíčová slova:

Alzheimer's disease – Biotin – Cognitive impairment – Dementia – Estrogens – Randomized controlled trials – Zinc – Estrogen replacement therapy


1. Updated Alzheimer’s Statistics report. The Alzheimer’s Association Facts and Figure (2019).

2. RAND Corporation, press release. Cost of Dementia Tops $159 Billion Annually in the United States (2013).

3. Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology. 2007; 29(1–2):125–32. doi: 10.1159/000109998 17975326

4. Langa KM, Larson EB, Crimmins EM, Faul JD, Levine DA, Kabeto MU, et al. A comparison of the prevalence of dementia in the United States in 2000 and 2012. JAMA internal medicine. 2017;177(1):51–8. doi: 10.1001/jamainternmed.2016.6807 27893041

5. Alzheimer’s Disease and Related Clinical Trials (2019).

6. Goya RG, Lehmann M, Chiavellini P, Canatelli-Mallat M, Hereñú CB, Brown OA. Rejuvenation by cell reprogramming: a new horizon in gerontology. Stem Cell Res Ther. 2018 Dec 17;9(1):349. doi: 10.1186/s13287-018-1075-y 30558644

7. Bonkowski MS, Sinclair DA. Slowing ageing by design: the rise of NAD+ and sirtuin-activating compounds. Nature reviews Molecular cell biology. 2016;17(11):679. doi: 10.1038/nrm.2016.93 27552971

8. Zhang Y, Kim MS, Jia B, Yan J, Zuniga-Hertz JP, Han C, et al. Hypothalamic stem cells control ageing speed partly through exosomal miRNAs. Nature. 2017; 548(7665):52. doi: 10.1038/nature23282 28746310

9. Saavedra JM. Evidence to consider angiotensin II receptor blockers for the treatment of early Alzheimer’s disease. Cellular and molecular neurobiology. 2016;36(2):259–79. doi: 10.1007/s10571-015-0327-y 26993513

10. Kisler K, Nelson AR, Montagne A, Zlokovic BV. Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. Nature Reviews Neuroscience. 2017;18(7):419. doi: 10.1038/nrn.2017.48 28515434

11. Mok SA, Condello C, Freilich R, Gillies A, Arhar T, Oroz J, et al. Mapping interactions with the chaperone network reveals factors that protect against tau aggregation. Nature structural & molecular biology. 2018; 25(5):384.

12. El-Dessouki AM, Galal MA, Awad AS, Zaki HF. Neuroprotective effects of simvastatin and cilostazol in L-methionine-induced vascular dementia in rats. Molecular neurobiology. 2017; 54(7):5074–84. doi: 10.1007/s12035-016-0051-8 27544235

13. Kim SH, Kandiah N, Hsu JL, Suthisisang C, Udommongkol C, Dash A. Beyond symptomatic effects: potential of donepezil as a neuroprotective agent and disease modifier in Alzheimer’s disease. British journal of pharmacology. 2017;174(23):4224–32. doi: 10.1111/bph.14030 28901528

14. Fahy GM, Brooke RT, Watson JP, Good Z, Vasanawala SS, Maecker H, Leipold MD, Lin DTS, Kobor MS, Horvath S. Reversal of epigenetic aging and immunosenescent trends in humans. Aging Cell. 2019 Sep 8:e13028.

15. Mehta D, Jackson R, Paul G, Shi J, Sabbagh M. Why do trials for Alzheimer’s disease drugs keep failing? A discontinued drug perspective for 2010–2015. Expert opinion on investigational drugs. 2017;26(6):735–9. doi: 10.1080/13543784.2017.1323868 28460541

16. McCleery J, Abraham RP, Denton DA, Rutjes AW, Chong LY, Al‐Assaf AS, Griffith DJ, Rafeeq S, Yaman H, Malik MA, Di Nisio M. Vitamin and mineral supplementation for preventing dementia or delaying cognitive decline in people with mild cognitive impairment. Cochrane Database of Systematic Reviews. 2018(11).

17. National Alzheimer’s Coordination Center (2018).

18. National Social Life, Health, and Aging Project (NSHAP): Wave 2 and Partner Data Collection (2018).

19. The National Ambulatory Medical Care Surveys (NAMCS) (2018).

20. Pourhoseingholi M. A., Baghestani A. R., & Vahedi M. (2012). How to control confounding effects by statistical analysis. Gastroenterology and hepatology from bed to bench, 5(2), 79–83. 24834204

21. McNamee R. Regression modelling and other methods to control confounding. Occup Environ Med. 2005;62(7):500–6, 472. doi: 10.1136/oem.2002.001115 15961628

22. Office support: LINEST function (2019).

23. Glenn Israel: Determining sample size (2019).

24. Appleby BS, Nacopoulos D, Milano N, Zhong K, Cummings JL. A review: treatment of Alzheimer’s disease discovered in repurposed agents. Dementia and geriatric cognitive disorders. 2013;35(1–2):1–22. doi: 10.1159/000345791 23307039

25. Mittal S, Bjørnevik K, Im DS, Flierl A, Dong X, Locascio JJ, et al. β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s disease. Science. 2017;357(6354):891–8. doi: 10.1126/science.aaf3934 28860381

26. Anagnostouli M, Livaniou E, Nyalala JO, Evangelatos G, Zournas C, Ithakissios DS, et al. Cerebrospinal fluid levels of biotin in various neurological disorders. Acta neurologica scandinavica. 1999; 99(6):387–92. doi: 10.1111/j.1600-0404.1999.tb07369.x 10577274

27. Method of treating multiple sclerosis. (2018). US 9,351,961.

28. Gold PE. Regulation of memory–From the adrenal medulla to liver to astrocytes to neurons. Brain research bulletin. 2014;105:25–35. doi: 10.1016/j.brainresbull.2013.12.012 24406469

29. Tai J, Liu W, Li Y, Li L, Hölscher C. Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer’s disease. Brain research. 2018;1678: 64–74. doi: 10.1016/j.brainres.2017.10.012 29050859

30. Park JH, Kim JN, Jang BC, Im SS, Song DK, Bae JH. Glucosamine suppresses platelet-activating factor-induced activation of microglia through inhibition of store-operated calcium influx. Environmental toxicology and pharmacology. 2016; 42:1–8. doi: 10.1016/j.etap.2015.12.014 26745504

31. Jutley G, Luk SM, Dehabadi MH, Cordeiro MF. Management of glaucoma as a neurodegenerative disease. Neurodegenerative disease management. 2017; 7(2):157–72. doi: 10.2217/nmt-2017-0004 28540772

32. Akbari E, Asemi Z, Daneshvar Kakhaki R, Bahmani F, Kouchaki E, Tamtaji OR. Effect of probiotic supplementation on cognitive function and metabolic status in Alzheimer’s disease: a randomized, double-blind and controlled trial. Frontiers in aging neuroscience. 2016; 8:256. doi: 10.3389/fnagi.2016.00256 27891089

33. Lu N, Dubreuil M, Zhang Y, Neogi T, Rai SK, Ascherio A, et al. Gout and the risk of Alzheimer’s disease: a population-based, BMI-matched cohort study. Annals of the rheumatic diseases. 2016; 75(3):547–51. doi: 10.1136/annrheumdis-2014-206917 25739830

34. Zhang Q, Lan Y, He XF, Luo CM, Wang QM, Liang FY, et al. Allopurinol protects against ischemic insults in a mouse model of cortical microinfarction. Brain research. 2015; 1622:361–7. doi: 10.1016/j.brainres.2015.07.010 26187758

35. Dregan A, Chowienczyk P, Gulliford MC. Are inflammation and related therapy associated with all-cause dementia in a primary care population?. Journal of Alzheimer’s Disease. 2015;46(4):1039–47. doi: 10.3233/JAD-150171 26402631

36. Grinde B, Engdahl B. Prescription database analyses indicates that the asthma medicine montelukast might protect against dementia: a hypothesis to be verified. Immunity & Ageing. 2017; 14(1):20.

37. Lehrer S, Rheinstein PH. Nasal Steroids as a Possible Treatment for Alzheimer’s Disease. Discovery medicine. 2017;24(132):147–52. 29272691

38. Liu CT, Wu BY, Hung YC, Wang LY, Lee YY, Lin TK, et al. Decreased risk of dementia in migraine patients with traditional Chinese medicine use: a population-based cohort study. Oncotarget. 2017; 8(45):79680. doi: 10.18632/oncotarget.19094 29108348

39. Lee SY, Lim JS, Oh DJ, Kong IG, Choi HG. Increased risk of neurodegenerative dementia in women with migraines: A nested case–control study using a national sample cohort. Medicine. 2019;98(7).

40. Weinstein G, Davis-Plourde KL, Conner S, Himali JJ, Beiser AS, Lee A, et al. Association of metformin, sulfonylurea and insulin use with brain structure and function and risk of dementia and Alzheimer’s disease: Pooled analysis from 5 cohorts. PloS one. 2019;14(2):e0212293. doi: 10.1371/journal.pone.0212293 30768625

41. Bohlken J, Jacob L, Kostev K. Association between the use of antihyperglycemic drugs and dementia risk: a case-control study. Journal of Alzheimer’s Disease. 2018 Jan 1(Preprint):1–8.

42. Kumar A, Singh N. Inhibitor of phosphodiestearse-4 improves memory deficits, oxidative stress, neuroinflammation and neuropathological alterations in mouse models of dementia of Alzheimer’s type. Biomedicine & Pharmacotherapy. 2017; 88:698–707.

43. Kim MY, Noh Y, Son SJ, Shin S, Paik HY, Lee S, et al. Effect of Cilostazol on Incident Dementia in Elderly Men and Women with Ischemic Heart Disease. Journal of Alzheimer’s Disease. 2018; 63(2):635–44. doi: 10.3233/JAD-170895 29660935

44. Jacobs V, Graves KG, Bunch TJ. Anticoagulant use in atrial fibrillation and risk of dementia: review of contemporary knowledge. Expert review of cardiovascular therapy. 2017;15(12):897–903. doi: 10.1080/14779072.2017.1411189 29179605

45. Walker V, Davies N, Martin R, Kehoe P. Comparison of antihypertensive drug classes for dementia prevention. BioRxiv. 2019 Jan 1:517482.

46. Chen VC, Wu SI, Huang KY, Yang YH, Kuo TY, Liang HY, et al Herpes Zoster and Demen.tia: A Nationwide Population-Based Cohort Study. The Journal of clinical psychiatry. 2018;79(1).

47. Sanborn V, Azcarate-Peril MA, Updegraff J, Manderino LM, Gunstad J. A randomized clinical trial examining the impact of LGG probiotic supplementation on psychological status in middle-aged and older adults. Contemporary clinical trials communications. 2018;12:192–7. doi: 10.1016/j.conctc.2018.11.006 30511028

48. Wroolie TE, Chen K, Watson KT, Iagaru A, Sonni I, Snyder N, et al. An 8-week open label trial of l-Threonic Acid Magnesium Salt in patients with mild to moderate dementia. Personalized Medicine in Psychiatry. 2017; 4:7–12.

49. Tarleton EK, Littenberg B, MacLean CD, Kennedy AG, Daley C. Role of magnesium supplementation in the treatment of depression: A randomized clinical trial. PLoS One. 2017;12(6):e0180067. doi: 10.1371/journal.pone.0180067 28654669

50. Campbell JM, Stephenson MD, Courten BD, Chapman I, Bellman SM, Aromataris E. Metformin Use Associated with Reduced Risk of Dementia in Patients with Diabetes: A Systematic Review and Meta-Analysis. Journal of Alzheimer’s Disease. 2018(Preprint):1–2.

51. Hervás D, Fornés-Ferrer V, Gómez-Escribano AP, Sequedo MD, Peiró C, Millán JM, et al. Metformin intake associates with better cognitive function in patients with Huntington’s disease. PloS one. 2017;12(6):e0179283. doi: 10.1371/journal.pone.0179283 28632780

52. Manzo C, Serra-Mestres J, Castagna A, Isetta M. Behavioral, Psychiatric, and Cognitive Adverse Events in Older Persons Treated with Glucocorticoids. Medicines. 2018;5(3):82.

53. Echouffo-Tcheugui JB, Conner SC, Himali JJ, Maillard P, DeCarli CS, Beiser AS, et al. Circulating cortisol and cognitive and structural brain measures: The Framingham Heart Study. Neurology. 2018;91(21):e1961–70. doi: 10.1212/WNL.0000000000006549 30355700

54. Ren X, Boriero D, Chaiswing L, Bondada S, Clair DK, Butterfield DA. Plausible biochemical mechanisms of chemotherapy-induced cognitive impairment (“chemobrain”), a condition that significantly impairs the quality of life of many cancer survivors. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2019 Feb 10.

55. Gibson EM, Nagaraja S, Ocampo A, Tam LT, Wood LS, Pallegar PN, et al. Methotrexate Chemotherapy Induces Persistent Tri-glial Dysregulation that Underlies Chemotherapy-Related Cognitive Impairment. Cell. 2019;176(1–2):43–55. doi: 10.1016/j.cell.2018.10.049 30528430

56. Gomm W, von Holt K, Thomé F, Broich K, Maier W, Fink A, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA neurology. 2016;73(4):410–6. doi: 10.1001/jamaneurol.2015.4791 26882076

57. Park SK, Baek YH, Pratt N, Ellett LK, Shin JY. The uncertainty of the association between proton pump inhibitor use and the risk of dementia: prescription sequence symmetry analysis using a Korean healthcare database between 2002 and 2013. Drug safety. 2018;41(6):615–24. doi: 10.1007/s40264-018-0638-2 29397553

58. Carrasco L, Alonso R, Pisa D, Rabano A. Alzheimer’s disease and fungal infection. Handbook of Infection and Alzheimer’s Disease. 2017; 5:281–94.

59. van Beers M, Janssen DJ, Gosker HR, Schols AM. Cognitive impairment in chronic obstructive pulmonary disease: disease burden, determinants and possible future interventions. Expert review of respiratory medicine. 2018;12(12):1061–74. doi: 10.1080/17476348.2018.1533405 30296384

60. Kivipelto M, Mangialasche F, Ngandu T. Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease. Nature Reviews Neurology. 2018 Oct 5:1.

61. Saavedra JM. Beneficial effects of Angiotensin II receptor blockers in brain disorders. Pharmacological research. 2017; 125:91–103. doi: 10.1016/j.phrs.2017.06.017 28711402

62. Bredesen DE, Sharlin K, Jenkins D, Okuno M, Youngberg W. Reversal of cognitive decline: 100 patients. J Alzheimers Dis Parkinsonism. 2018; 8(450):2161–0460.

63. Iskra R, Antonyak H. Chromium in Health and Longevity. In Trace Elements and Minerals in Health and Longevity 2018 (pp. 133–162). Springer, Cham.

64. Riveron-Negrete L, Fernandez-Mejia C. Pharmacological effects of biotin in animals. Mini reviews in medicinal chemistry. 2017;17(6):529–40. doi: 10.2174/1389557516666160923132611 27670579

65. Tourbah A, Lebrun-Frenay C, Edan G, Clanet M, Papeix C, Vukusic MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: a randomised, double-blind, placebo-controlled study. Multiple Sclerosis Journal. 2016;22(13):1719–31. doi: 10.1177/1352458516667568 27589059

66. Huang YM, Dou HL, Huang FF, Xu XR, Zou ZY, Lu XR, et al. Changes following supplementation with lutein and zeaxanthin in retinal function in eyes with early age-related macular degeneration: a randomised, double-blind, placebo-controlled trial. British Journal of Ophthalmology. 2015; 99(3):371–5. doi: 10.1136/bjophthalmol-2014-305503 25228440

67. Mocchegiani E, Malavolta M. Role of Zinc and Selenium in Oxidative Stress and Immunosenescence: Implications for Healthy Aging and Longevity. Handbook of Immunosenescence: Basic Understanding and Clinical Implications. 2018:1–35.

68. Lages LC, Lopez J, Lopez-Medrano AM, Atlas SE, Martinez AH, Woolger JM, et al. A double-blind, randomized trial on the effect of a broad-spectrum dietary supplement on key biomarkers of cellular aging including inflammation, oxidative stress, and DNA damage in healthy adults. J. Clin. Transl. Res. 2017;2(4):135–43. 30873472

69. Kirkland A, Sarlo G, Holton K. The role of magnesium in neurological disorders. Nutrients. 2018;10(6):730.

70. Tarleton EK, Littenberg B, MacLean CD, Kennedy AG, Daley C. Role of magnesium supplementation in the treatment of depression: A randomized clinical trial. PLoS One. 2017;12(6):e0180067. doi: 10.1371/journal.pone.0180067 28654669

71. Renzi-Hammond L, Bovier E, Fletcher L, Miller L, Mewborn C, Lindbergh C, Baxter J, Hammond B. Effects of a lutein and zeaxanthin intervention on cognitive function: A randomized, double-masked, placebo-controlled trial of younger healthy adults. Nutrients. 2017; 9(11):1246.

72. Hammond BR Jr, Miller LS, Bello MO, Lindbergh CA, Mewborn C, Renzi-Hammond LM. Effects of lutein/zeaxanthin supplementation on the cognitive function of community dwelling older adults: A randomized, double-masked, placebo-controlled trial. Frontiers in Aging Neuroscience. 2017; 9:254. doi: 10.3389/fnagi.2017.00254 28824416

73. Bredesen DE. Reversal of cognitive decline: a novel therapeutic program. Aging (Albany NY). 2014 Sep;6(9):707–17.

74. Ngandu T, Lehtisalo J, Solomon A, Levälahti E, Ahtiluoto S, Antikainen R, Bäckman L, Hänninen T, Jula A, Laatikainen T, Lindström J. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. The Lancet. 2015;385(9984):2255–63.

75. Wroolie TE, Chen K, Watson KT, Iagaru A, Sonni I, Snyder N, et al. An 8-week open label trial of l-Threonic Acid Magnesium Salt in patients with mild to moderate dementia. Personalized Medicine in Psychiatry. 2017; 4:7–12.

76. Hejl A, Høgh P, Waldemar G. Potentially reversible conditions in 1000 consecutive memory clinic patients. Journal of Neurology, Neurosurgery & Psychiatry. 2002; 73(4):390–4.

77. McCarney R, Warner J, Iliffe S, Van Haselen R, Griffin M, Fisher P. The Hawthorne Effect: a randomised, controlled trial. BMC medical research methodology. 2007;7(1):30.

78. Aerts L, Heffernan M, Kochan NA, Crawford JD, Draper B, Trollor JN, et al. Effects of MCI subtype and reversion on progression to dementia in a community sample. Neurology. 2017;88(23):2225–32. doi: 10.1212/WNL.0000000000004015 28490651

79. Andrieu S, Coley N, Lovestone S, Aisen PS, Vellas B. Prevention of sporadic Alzheimer’s disease: lessons learned from clinical trials and future directions. The Lancet Neurology. 2015;14(9):926–44. doi: 10.1016/S1474-4422(15)00153-2 26213339

80. Mayburd AL, Baranova A. Increased lifespan and improved cognition in osteoarthritis points to immunological determinants of mortality rate and cognitive decline. (in submission).

Článek vyšel v časopise


2019 Číslo 11